Company Description
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States.
Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair.
It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Théa Open Innovation for the development KIO-301.
The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021.
Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Dr. Brian M. Strem Ph.D. |
Contact Details
Address: 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 United States | |
| Phone | 781-788-8869 |
| Website | kiorapharma.com |
Stock Details
| Ticker Symbol | KPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001372514 |
| CUSIP Number | 49721T101 |
| ISIN Number | US49721T3095 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brian M. Strem Ph.D. | President, Chief Executive Officer and Director |
| Melissa Tosca CPA | Executive Vice President of Finance |
| Dr. Eric J. Daniels M.B.A., M.D. | Chief Development Officer |
| Dr. Stefan Sperl Ph.D. | Executive Vice President of CMC and Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | 8-K | Current Report |
| Jun 7, 2024 | 8-K | Current Report |
| May 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 10, 2024 | 8-K | Current Report |
| May 10, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 3, 2024 | 8-K | Current Report |
| Mar 28, 2024 | EFFECT | Notice of Effectiveness |
| Mar 28, 2024 | 424B3 | Prospectus |